$BBIO News

HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $120

BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play

BridgeBio Announces Publication Of New Analyses In Circulation: Heart Failure, Examining Kidney Function In Individuals With Transthyretin Amyloid Cardiomyopathy Treated With Acoramidis

BridgeBio: 3 New Drug Approvals In Sight Outweigh Attruby Issues, Still Bullish

Reported Sunday, BridgeBio PROPEL 3 Phase 3 Trial Published In NEJM, Oral Infigratinib Demonstrates Statistically Significant Improvements In Height, Body Proportionality In Achondroplasia

BridgeBio Pharma To Share Additional Data From PROPEL 3, Its Phase 3 Pivotal Study Of Oral Infigratinib In Children Living With Achondroplasia, In A Late Breaking Oral Presentation At The International Congress Of Children’s Bone Health, June 27-30

Mizuho Maintains Outperform on BridgeBio Pharma, Lowers Price Target to $96

Canaccord Genuity Initiates Coverage On BridgeBio Pharma with Buy Rating, Announces Price Target of $104

Does FDA Priority Review for First LGMD Therapy Change The Bull Case For BridgeBio Pharma (BBIO)?

Morgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $98

HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $110 Price Target

BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9

BridgeBio Announces FDA Acceptance Of Its New Drug Application With Priority Review For Oral BBP-418 For The Treatment Of Individuals Living With Limb-Girdle Muscular Dystrophy Type 2I/R9; FDA Sets PDUFA Date Of November 27

Raymond James Downgrades BridgeBio Pharma to Market Perform

Citigroup Initiates Coverage On BridgeBio Pharma with Neutral Rating, Announces Price Target of $82

How Encaleret’s NDA and New Acoramidis Milestones Could Reframe BridgeBio Pharma (BBIO) Investors’ Outlook

Evercore ISI Retains an “Outperform Rating” on BridgeBio Pharma, Inc. (BBIO)

BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches

BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcript

BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 - Slideshow